APPLICATION NUMBER:
050803Orig1s000

CHEMISTRY REVIEW(S)
NDA 50-803

VELTIN™ (Clindamycin Phosphate and Tretinoin) Gel
1.2%/0.025%

Stiefel, a GSK Company

CMC Review
for
Division of Dermatology and Dental Products

Shulin Ding, Ph.D.

Branch IV, Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
# Table of Contents

- Table of Contents .....................................................................................................2

- Chemistry Review Data Sheet...............................................................................3

- The Executive Summary ..........................................................................................8

  I. Recommendations..................................................................................................8  
   A. Recommendation and Conclusion on Approvability ..........................................8  
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable ..................................8  

  II. Summary of Chemistry Assessments..................................................................8  
    A. Description of the Drug Product(s) and Drug Substance(s) ..............................8  
    B. Description of How the Drug Product is Intended to be Used .........................9  
    C. Basis for Approvability or Not-Approval Recommendation ..............................10  

  III. Administrative...................................................................................................10  
    A. Reviewer’s Signature ..........................................................................................10  
    B. Endorsement Block ...........................................................................................10  
    C. CC Block ...........................................................................................................10  

- Chemistry Assessment ..........................................................................................11  

  I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data......11  
   S DRUG SUBSTANCE [Name, Manufacturer] ..........................................................11  
   P DRUG PRODUCT [Name, Dosage form] ...............................................................13  
   A APPENDICES ......................................................................................................45  
   R REGIONAL INFORMATION ..................................................................................46  

  II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ..................47  
    A. Labeling & Package Insert ..............................................................................47  
    B. Environmental Assessment Or Claim Of Categorical Exclusion ......................55  

  III. List Of Pending Deficiencies ............................................................................55
Chemistry Review Data Sheet

1. NDA 50-803

2. REVIEW #: 2

3. REVIEW DATE: June 22, 2010

4. REVIEWER: Shulin Ding, Ph.D.

5. PREVIOUS DOCUMENTS: N/A

<table>
<thead>
<tr>
<th>Submission(s)</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>Aug. 23, 2004</td>
</tr>
<tr>
<td>Amendment¹</td>
<td>Oct. 8, 2004</td>
</tr>
<tr>
<td>Amendment²</td>
<td>Nov. 22, 2004</td>
</tr>
<tr>
<td>Amendment³</td>
<td>Dec. 6, 2004</td>
</tr>
<tr>
<td>Amendment⁴</td>
<td>Jan. 28, 2005</td>
</tr>
<tr>
<td>Amendment⁵</td>
<td>Feb. 17, 2005</td>
</tr>
<tr>
<td>Amendment⁶</td>
<td>March 2, 2005</td>
</tr>
<tr>
<td>Amendment⁷</td>
<td>March 8, 2005</td>
</tr>
<tr>
<td>Amendment⁸</td>
<td>March 22, 2005</td>
</tr>
<tr>
<td>Amendment⁹</td>
<td>April 5, 2005</td>
</tr>
<tr>
<td>Amendment¹⁰</td>
<td>April 22, 2005</td>
</tr>
<tr>
<td>Amendment¹¹</td>
<td>May 12, 2005</td>
</tr>
<tr>
<td>Amendment¹²</td>
<td>May 16, 2005</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment¹³</td>
<td>Nov. 27, 2009</td>
</tr>
<tr>
<td>Amendment¹⁴</td>
<td>Dec. 22, 2009</td>
</tr>
<tr>
<td>Amendment¹⁵</td>
<td>Feb. 12, 2010</td>
</tr>
<tr>
<td>Amendment¹⁶</td>
<td>March 12, 2010</td>
</tr>
<tr>
<td>Amendment¹⁷</td>
<td>March 17, 2010</td>
</tr>
<tr>
<td>Amendment¹⁸</td>
<td>May 4, 2010 and May 5, 2010</td>
</tr>
<tr>
<td>Amendment¹⁹</td>
<td>May 24, 2010</td>
</tr>
<tr>
<td>Amendment²⁰</td>
<td>June 1, 2010</td>
</tr>
<tr>
<td>Amendment²¹</td>
<td>June 15, 2010</td>
</tr>
<tr>
<td>See footnote</td>
<td></td>
</tr>
</tbody>
</table>

¹The 10/8/04 amendment provides for a response to clinical and CMC questions.
The 12/6/04 amendment provides for a response to the chemist’s request for samples contained in the NDA filing review letter dated Nov. 5, 2004.
The 1/28/05 amendment provides for an additional comparability protocol.
The 2/17/05 amendment provides for copies of foreign labels.
The 3/2/05 amendment provides for two additional proposed proprietary trade names.
The 3/8/05 amendment provides for supporting data for the proposed trade names.
The 3/22/05 amendment provides for a response to CMC information request dated March 14, 2005.
The 4/5/05 amendment provides for a response to CMC information request on comparability protocols dated March 29, 2005.
The 4/22/05 amendment provides for a partial response to CMC information request dated April 15, 2005.
The 5/12/05 amendment provides for a response to CMC information request dated April 15, 2005.
The 5/16/05 amendment provides for a response to CMC information request dated April 15 and 28, 2005 regarding analytical methods and method validation.
The 11/27/09 and 12/22/09 amendments provide for the addition and deletion of a packaging site.
The 3/12/2010 amendment provides for a response to the Agency’s labeling comments conveyed in the IR letter dated March 4, 2010.
The 3/17/2010 amendment provides for a response to the Agency’s questions conveyed in teleconferences dated March 5, 9 and 11, 2010 regarding product appearance/dosage form. The amendment includes the submission of six drug product samples as requested by the Agency in the teleconferences.
The 6/1/2010 amendment provides for a revised labeling.
The 6/15/2010 amendment provides for a revised labeling which contains all CMC-recommended changes.
Received via e-mail on 6/22/2010. It provides for the final version of carton/container labels. An official amendment submitted to CDER document room is said to follow by the applicant in the e-mail.

7. NAME & ADDRESS OF APPLICANT:

Name: Stiefel, a GSK Company
Address: 20 TW Alexander Dr. Research Triangle Park, NC 27709
Representative: Salisa Hauptmann, Vice President, Global Regulatory Affairs
Telephone: 919-990-6133

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: VELTIN™ Gel
b) Non-Proprietary Name (USAN): Clindamycin phosphate and tretinoin
c) Code Name/# (ONDQA only): None
d) Chem. Type/Submission Priority (ONDQA only):
   - Chem. Type: 4
   - Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(2)

10. PHARMACOL. CATEGORY: Skin agent
    Clindamycin Phosphate – Antibiotic
    Tretinoin - Retinoid

Page 4 of 61
11. DOSAGE FORM:    Gel

12. STRENGTH/POTENCY:   Clindamycin Phosphate 1.2%,  Tretinoin 0.025%

13. ROUTE OF ADMINISTRATION:   Topical

14. Rx/OTC DISPENSED:      x Rx    ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    ______SPOTS product – Form Completed
    ___X___ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Clindamycin Phosphate
INN Name: Clindamycin phosphate
Compendial Name: Clindamycin phosphate, USP
Chemical Name: Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-
pyrrolidinylcarboxamido)-1-thio-L-threo-a-D-galacto-octopyranoside
2-(dihydrogen phosphate) or (7-(S)-chloro-7-deoxylincomycin-2-
phosphate)
CAS Registry Number: 24729-96-2
Molecular Formula: C_{18}H_{34}ClN_{2}O_{8}PS
Molecular weight: 504.97 g/mole

Tretinoin
INN Name: Tretinoin
Compendial Name: Tretinoin, USP
Chemical Name: all-trans 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-
nonatetraenoin acid
CAS Registry Number: 302-79-4
Molecular Formula: C_{20}H_{28}O_{2}
Molecular weight: 300.44 g/mole
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>(b) 4</td>
<td></td>
<td>(b) 4</td>
<td>3</td>
<td>Adequate</td>
<td>Oct. 9, 2009</td>
<td>Reviewed by Mahnaz Farahani on 10/07/2009, and deemed adequate to support ANDA 90-785 (Clindamycin phosphate foam 1%, Cobrek Pharmaceuticals). There have been no technical changes in the DMF since the review.</td>
</tr>
<tr>
<td>II</td>
<td>1</td>
<td>Adequate</td>
<td>3/9/2010</td>
<td></td>
<td>5/8/2008</td>
<td></td>
<td>Reviewed by Shulin Ding</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
<td>Adequate</td>
<td>5/8/2008</td>
<td></td>
<td></td>
<td></td>
<td>(b) 4 has been reviewed and deemed acceptable (see the DMF review by Bogdan Kurtyka dated 5/8/2008). No significant changes since the review. Extractable studies were conducted to meet the limits outlined in the USP &lt;661&gt; and 21CFR 175.300, indicating they are qualified for pharmaceutical uses and also safe to contact food.</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table: 1 – DMF Reviewed. Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>65,369</td>
<td>Original IND dated Oct. 23, 2002</td>
</tr>
</tbody>
</table>

18. STATUS:

ONDC:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Not applicable</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>3/18/2010</td>
<td>E. Johnson</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Acceptable</td>
<td>2/16/2010 and 3/4/2010</td>
<td>Jill Merrill, Ph.D.</td>
</tr>
<tr>
<td>Biopharm</td>
<td>Not needed</td>
<td>1/21/10</td>
<td>Tapash Ghosh</td>
</tr>
<tr>
<td>DMEPA</td>
<td>Acceptable (proprietary name)</td>
<td>4/20/10</td>
<td>Zachary Olesczuk</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not planned</td>
<td>6/3/10</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
<tr>
<td>Environment Assessment</td>
<td>Acceptable.</td>
<td>5/3/10</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Not applicable</td>
<td>5/3/10</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only): N/A
The Chemistry Review for NDA 50-803

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA has provided sufficient CMC information to assure the identity, strength, purity, and quality of the drug product. All facilities involved are in compliance with cGMP, and labels/labeling have adequate information required. Therefore, from a CMC perspective, this NDA is recommended for “Approval”.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1) Drug Product

This submission is a Class 2 resubmission of NDA 50803. NDA 50803 Velac gel received a “not approvable” action in the first cycle review due to a positive signal observed following exposure to Velac gel in both the vehicle and clindamycin arms of a carcinogenicity study in a Tg.AC mouse model. The applicant has reformulated since then, and resubmitted the NDA with the new formulation, Veltin gel. The new formulation, Veltin gel, is very similar to Velac gel in appearance and composition. The only formulation differences are that Veltin gel does not contain whereas Velac gel did and Veltin gel in Velac gel

The proposed product, Veltin gel, is a yellowish, opaque, aqueous gel containing two commercially available, USP grade active pharmaceutical ingredients: clindamycin phosphate (1.2% equivalent to 1% of clindamycin) and tretinoin (0.025%). Both clindamycin phosphate and tretinoin are fully solubilized in the formulation. The turbidity of the gel is an inherent property of the gel vehicle although it is unclear how the turbidity is produced.

Veltin gel is filled into aluminum tubes, sealed at the neck and capped with a white screw cap. At time of use, the aluminum seal is punctured to allow the formulation to be squeezed out. Veltin gel is proposed to be supplied in 30 g tubes.

The formulation of Veltin gel is consist of nine compendial excipients (butylated hydroxytoluene, Carbomer 940, citric acid anhydrous, edetate disodium, methylparaben, propylene glycol, tromethamine and purified water), and one non-compendial (POE-4) which is incorporated in the formulation. POE-4 is listed in the FDA inactive
CHEMISTRY REVIEW

Chemistry Assessment Section

ingredient database, and has been used in approved topical products with a maximum concentration of 5.22%.

The proposed to-be marketed formulation is the same formulation used in the Phase 3 clinical study. It is also the same formulation used in the bioavailability study, and the registration stability studies.

The real time long term stability data (12-30 months from four commercial scale batches) provided in the resubmission support the proposed 18 months expiration dating period for Veltin gel 30 g tubes stored at a controlled room temperature of 68-77°F (20-25°C). The proposed expiration dating period with storage condition is, therefore, acceptable.

2) Drug Substance

There are two drug substances involved in this NDA: clindamycin phosphate, USP, and tretinoin, USP. Their solid properties such as polymorph and particle size are not critical to the quality of the proposed drug product because the formulation and the manufacturing process of the proposed drug product are designed to ensure a complete solubilization of clindamycin phosphate and tretinoin.

Clindamycin phosphate:

Clindamycin phosphate is very water soluble.

Clindamycin phosphate is a pro-drug of clindamycin. It is inactive in vitro. Topical application initiates hydrolysis to the formation of available or free clindamycin.

The applicant references DMF for clindamycin phosphate drug substance. DMF was most recently reviewed on Oct.7, 2009, for ANDA 90-785 (Clindamycin phosphate foam 1%, Cobrek Pharmaceuticals, Inc.), and deemed adequate to support the ANDA. No technical changes in the DMF have been reported to the Agency since the last review. DMF is, therefore, concluded to be adequate to support NDA 50-803.

Tretinoin:

Tretinoin is sparingly soluble in water. It degrades upon exposure to oxygen and light (both visible and UV).

The applicant references DMF for tretinoin drug substance. DMF has been reviewed and deemed adequate to support this NDA (DMF Chemistry Review #7 by Shulin Ding on March 9, 2010).

B. Description of How the Drug Product is Intended to be Used

The drug product is intended for topical treatment of acne vulgaris. It should be applied once daily in the evening, using a pea size amount to lightly cover the entire affected area. Avoid the eyes, lips, and mucous membranes.
The drug product is supplied in 30 g aluminum tubes.

C. Basis for Approvability or Not-Approval Recommendation

The NDA provided adequate information on the drug substances, formulation, the raw material controls, manufacturing process, specifications, and container/closures. It also provided sufficient stability data to assure the strength, purity, and quality of the drug product throughout its shelf-life. On March 18, 2010, the Office of Compliance has issued an “acceptable” overall recommendation for all the facilities involved (Attachment 1). The proposed proprietary name, Veltin™, has been accepted by DMEPA. Labels/labeling have required information.

III. Administrative

A. Reviewer’s Signature: in DARRTS

B. Endorsement Block: in DARRTS

C. CC Block: in DARRTS
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-50803</td>
<td>ORIG-1</td>
<td>STIEFEL A GSK CO</td>
<td>Veltin</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHULIN DING
06/24/2010

MOO JHONG RHEE
06/24/2010
Chief, Branch IV
NDA 50-803

Velac® (Clindamycin 1% - Tretinoin 0.025%) Gel

Connetics Corporation

Shulin Ding, Ph.D.

Division of Metabolic and Endocrine Drug Products

HFD-510
# Table of Contents

Table of Contents ........................................................................................................ 2

Chemistry Review Data Sheet ...................................................................................... 3

The Executive Summary .............................................................................................. 7

I. Recommendations ................................................................................................. 7
   A. Recommendation and Conclusion on Approvability ......................................... 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
      Management Steps, if Approvable ...................................................................... 7

II. Summary of Chemistry Assessments ........................................................................ 7
   A. Description of the Drug Product(s) and Drug Substance(s) ............................. 7
   B. Description of How the Drug Product is Intended to be Used ........................... 9
   C. Basis for Approvability or Not-Approval Recommendation ............................. 9

III. Administrative ..................................................................................................... 9
   A. Reviewer’s Signature ......................................................................................... 9
   B. Endorsement Block ......................................................................................... 9
   C. CC Block ....................................................................................................... 9

Chemistry Assessment .............................................................................................. 10

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body Of Data ...... 10
   S DRUG SUBSTANCE [Name, Manufacturer] ...................................................... 10
   P DRUG PRODUCT [Name, Dosage form] ........................................................ 16
   A APPENDICES .................................................................................................... 46
   R REGIONAL INFORMATION ............................................................................. 46

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 .......................... 47
   A. Labeling & Package Insert ............................................................................. 47
   B. Environmental Assessment Or Claim Of Categorical Exclusion ....................... 48

III. List Of Pending Deficiencies ............................................................................... 49
1. NDA 50-803

2. REVIEW #: 1

3. REVIEW DATE: June 1, 2005

4. REVIEWER: Shulin Ding, Ph.D.

5. PREVIOUS DOCUMENTS: N/A

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>Aug. 23, 2004</td>
</tr>
<tr>
<td>Amendment¹</td>
<td>Oct. 8, 2004</td>
</tr>
<tr>
<td>Amendment²</td>
<td>Nov. 22, 2004</td>
</tr>
<tr>
<td>Amendment³</td>
<td>Dec. 6, 2004</td>
</tr>
<tr>
<td>Amendment⁴</td>
<td>Jan. 28, 2005</td>
</tr>
<tr>
<td>Amendment⁵</td>
<td>Feb. 17, 2005</td>
</tr>
<tr>
<td>Amendment⁶</td>
<td>March 2, 2005</td>
</tr>
<tr>
<td>Amendment⁷</td>
<td>March 8, 2005</td>
</tr>
<tr>
<td>Amendment⁸</td>
<td>March 22, 2005</td>
</tr>
<tr>
<td>Amendment⁹</td>
<td>April 5, 2005</td>
</tr>
<tr>
<td>Amendment¹⁰</td>
<td>April 22, 2005</td>
</tr>
<tr>
<td>Amendment¹¹</td>
<td>May 12, 2005</td>
</tr>
<tr>
<td>Amendment¹²</td>
<td>May 16, 2005</td>
</tr>
</tbody>
</table>

¹The 10/8/04 amendment provides for a response to clinical and CMC questions.
³The 12/6/04 amendment provides for a response to the chemist’s request for samples contained in the NDA filing review letter dated Nov. 5, 2004.
⁴The 1/28/05 amendment provides for an additional comparability protocol.
⁵The 2/17/05 amendment provides for copies of foreign labels.
⁶The 3/2/05 amendment provides for two additional proposed proprietary trade names.
⁷The 3/8/05 amendment provides for supporting data for the proposed trade names.
⁸The 3/22/05 amendment provides for a response to CMC information request dated March 14, 2005.
⁹The 4/5/05 amendment provides for a response to comparability protocols dated March 29, 2005.
¹⁰The 4/22/05 amendment provides for a partial response to CMC information request dated April 15, 2005.
¹¹The 5/12/05 amendment provides for a response to CMC information request dated April 15, 2005.
¹²The 5/16/05 amendment provides for a response to CMC information request dated April 15 and 28, 2005 regarding analytical methods and method validation.
7. NAME & ADDRESS OF APPLICANT:

Name: Connetics Corporation
Address: 3290 West Bayshore Road, Palo Alto, CA 94303
Representative: Sharon L. Hall, Senior Director, Regulatory Affairs
Telephone: 650-843-2858

8. DRUG PRODUCT NAME/CODE/TYPEx:

a) Proprietary Name: Velac® Gel
b) Non-Proprietary Name (USAN): Clindamycin and tretinoin gel
c) Code Name/# (ONDC only): None
d) Chem. Type/Submission Priority (ONDC only):
   • Chem. Type: 4
   • Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505 (b)(2)

10. PHARMACOL. CATEGORY: Skin agent
    Clindamycin – Anti-infective
    Tretinoin - Retinoid

11. DOSAGE FORM: Gel

12. STRENGTH/POTENCY: Clindamycin 1%, Tretinoin 0.025%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED: x Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    ______SPOTS product – Form Completed
    ___X___ Not a SPOTS product
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Clindamycin Phosphate

INN Name: Clindamycin phosphate
Compendial Name: Clindamycin phosphate, USP
Chemical Name: Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate) or (7-(S)-chloro-7-deoxylincomycin-2-phosphate)

CAS Registry Number: 24729-96-2
Molecular Formula: C_{18}H_{34}ClN_{2}O_{8}PS
Molecular weight: 504.97 g/mole

Tretinoin

INN Name: Tretinoin
Compendial Name: Tretinoin, USP
Chemical Name: all-trans 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoin acid

CAS Registry Number: 302-79-4
Molecular Formula: C_{20}H_{28}O_{2}
Molecular weight: 300.44 g/mole
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE1</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>II</td>
<td>(b) (4)</td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>Sep. 8, 2003</td>
<td>Reviewed by Bart Ho, Chemistry Review #5. No significant changes since the review.</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td>3</td>
<td>Adequate</td>
<td>April 8, 2004</td>
<td>Reviewed by Liang-Lii Huang, Chemistry Review #4</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>4</td>
<td>Adequate</td>
<td>May 26, 2005</td>
<td>(b) (4)</td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table: 1 – DMF Reviewed. Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under “Comments”)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>65,369</td>
<td>Original IND dated Oct. 23, 2002</td>
</tr>
</tbody>
</table>

18. STATUS:

ONDC:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>Not applicable</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>EES</td>
<td>Pending</td>
<td>5/26/05</td>
<td>Jill Merrill, Ph.D.</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>Not Approvable</td>
<td>5/16/05</td>
<td>Chandra Chaurasia</td>
</tr>
<tr>
<td>Biopharm</td>
<td>Acceptable</td>
<td>4/26/05</td>
<td>Jinhee Jahng</td>
</tr>
<tr>
<td>DMETS</td>
<td>Unacceptable proprietary name</td>
<td>11/11/04</td>
<td>Jinhee Jahng</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Not planned</td>
<td>5/26/05</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
<tr>
<td>Environment Assessment</td>
<td>Acceptable</td>
<td>5/26/05</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Not applicable</td>
<td>5/26/05</td>
<td>Shulin Ding, Ph.D.</td>
</tr>
</tbody>
</table>

19. ORDER OF REVIEW (OGD Only): N/A
The Chemistry Review for NDA 50-803

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

NDA 50-803 is recommended for Approvable (AE) action from the standpoint of chemistry, manufacturing and controls (CMC).

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

1) Drug Product

The proposed drug product is an aqueous-based gel containing two commercially available, USP grade active pharmaceutical ingredients: clindamycin phosphate (expressed as 1% clindamycin) and tretinoin (0.025%). The gel is yellowish, slightly viscous, and translucent to slightly turbid. It has a smooth consistency. Both clindamycin phosphate and tretinoin are fully solubilized in the formulation of the proposed drug product.

The gel is filled into aluminum tubes, sealed at the neck with an aluminum seal, and capped with a white screw cap. At time of use, the aluminum seal is punctured to allow the formulation to be squeezed out. The proposed drug product is end-crimped and supplied in 30 g tubes.

The formulation of Velac gel consists of nine (9) compendial excipients (butylated hydroxytoluene, Carbomer 940, citric acid anhydrous, edetate disodium, methylparaben, propylene glycol, tromethamine and purified water), and non-compendial (POE-4). POE-4 is listed in the FDA inactive ingredient database, and has been used in approved topical products with a maximum concentration of 5.22%.

The proposed to-be marketed formulation is identical to the one used in the Phase 3 clinical studies.

Long term stability data (12 months, three batches) are provided for 30 g tube size. The batches meet the proposed product specification when stored at

Page 7 of 50
Chemistry Assessment Section

25°C/60%RH. A significant degradation was noticed in all of the samples stored under the accelerated condition, and the samples failed some of the proposed related substance criteria at the end of the accelerated studies (6 months). The 30°C samples also showed an upward trend in related substances.

The batch release and the primary stability data on clindamycin phosphate, its related substances, and (b) (4) were generated using an HPLC method (Method 73.5556) which was different from the proposed regulatory method (R0252). The batch release and the primary stability data on (b) (4) and (b) (4) have been accepted to support drug product expiry period and specification after bridging data were provided in the amendment dated May 16, 2005, showing that these two methods yield comparable results for these two tests. The batch release and the primary stability data provided in the original submission on (b) (4) and unspecified related substances are, however, concluded to be irrelevant because the two methods are not comparable for these tests.

As a result of the irrelevant data, the proposed acceptance criteria for clindamycin related substances are recommended as tentative. The criteria should be reviewed again when adequate relevant data become available.

The expiry period of the proposed drug product is recommended to be set based on real time data due to (1) the lack of release and stability data generated by the proposed regulatory method R0252, and (2) the significant drug degradation noticed in the accelerated stability studies. Submitted stability data support (b) (4) of expiry period for (b) (4) 30g (b) (4) of Velac Gel stored at a controlled room temperature of 68-77°F (20-25°C).

2) Drug Substance

There are two drug substances involved in this NDA: clindamycin phosphate, USP, and tretinoin, USP. Their solid properties such as polymorph and particle size are not critical to the quality of the proposed drug product because the formulation and the manufacturing process of the proposed drug product are designed to ensure a complete solubilization of clindamycin phosphate and tretinoin.

Cindamycin phosphate:

Clindamycin phosphate is very water soluble (b) (4)
Tretinoin:

Tretinoin is sparingly soluble in water. It degrades upon exposure to oxygen and light (both visible and UV). The applicant references DMF for tretinoin drug substance. DMF was most recently reviewed on June 8, 2004, for ANDA 76-498 (Tretinoin topical cream), and deemed adequate to support the ANDA. No changes have been reported to the agency since the last review. DMF is concluded to be adequate to support NDA 50-803.

B. Description of How the Drug Product is Intended to be Used

The drug product is intended for topical treatment of acne vulgaris. It should be applied once daily in the evening, using enough to lightly cover the entire affected area.

The drug product is supplied in 30 g aluminum tubes.

C. Basis for Approvability or Not-Approval Recommendation

NDA 21-688 is approvable from the standpoint of CMC pending an acceptable overall recommendation from Office of Compliance, and a satisfactory response for pending deficiencies listed on the last page of this review document.

III. Administrative

A. Reviewer’s Signature: in DFS

B. Endorsement Block: in DFS

C. CC Block: in DFS

41 Pages Have Been Withheld in Full Immediately Following this Page as B4 (CCI/TS)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Shulin Ding
6/2/05 09:27:54 AM
CHEMIST

Mamta Gautam-Basak
6/2/05 10:01:59 AM
CHEMIST
Concur, Approvable
NDA FILEABILITY CHECKLIST

NDA Number: (b) (4)  
Drug Name: Velac® Gel (Clindamycin 1% - Tretinoin 0.025%)

Applicant: Connetics Corporation, 3290 West Bayshore Rd., Palo Alto, CA 94303

IS THE CMC SECTION OF THIS APPLICATION FILEABLE? (Yes or No)  Yes

Table 1 Fileability Checklist
The following parameters are necessary for initiating a full review, e.g. complete enough for review but may have deficiencies.

<table>
<thead>
<tr>
<th>PARAMETER</th>
<th>YES</th>
<th>NO</th>
<th>COMMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Is the NDA organized adequately for its CMC content?</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2  Are the CMC sections adequately indexed &amp; paginated?</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3  Is the CMC sections legible?</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4  Are all facilities identified with full street addresses, contact</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>names &amp; CFN#s?</td>
<td></td>
<td></td>
<td>No CFN#. Only registration # provided.</td>
</tr>
<tr>
<td>5  Is there a statement that all facilities are prepared for GMP</td>
<td>x</td>
<td></td>
<td>CTD Module 3 3.2.P.3.1</td>
</tr>
<tr>
<td>inspections?</td>
<td></td>
<td></td>
<td>The only site in question is DP stability testing site, which is scheduled to be moved in January, 2005.</td>
</tr>
<tr>
<td>6  Has an environmental assessment or categorical exclusion been</td>
<td>x</td>
<td></td>
<td>CTD Module 1 1.3.5</td>
</tr>
<tr>
<td>provided?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7  Does the drug substance section contain controls?</td>
<td>x</td>
<td></td>
<td>CTD Module 3 3.2.S.4</td>
</tr>
<tr>
<td>8  Does the drug product section contain controls?</td>
<td>x</td>
<td></td>
<td>CTD Module 3 3.2.P.5</td>
</tr>
<tr>
<td>9  Has stability data been submitted to justify the requested expiry</td>
<td>x</td>
<td></td>
<td>CTD Module 3 3.2.P.8</td>
</tr>
<tr>
<td>date?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Has the applicant provided all requested data by the division</td>
<td>x</td>
<td></td>
<td>All requested are provided except method validation for potential interference from the other API and its degradants/impurities.</td>
</tr>
<tr>
<td>during the IND &amp; pre-NDA phases?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Have draft container labels been provided?</td>
<td>x</td>
<td></td>
<td>CTD Module 1 1.3.2.2</td>
</tr>
<tr>
<td>12 Has a draft package insert been provided?</td>
<td>x</td>
<td></td>
<td>CTD Module 1 1.3.2.1</td>
</tr>
<tr>
<td>13 Has an Investigational Formulations section been included?</td>
<td>x</td>
<td></td>
<td>CTD Module 3 3.2.P.2.2</td>
</tr>
<tr>
<td>14 Are there three Methods Validation documents?</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 Is a statistical consult required?</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 Is there a separate microbiological section? Is a micro</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>consult required?</td>
<td></td>
<td></td>
<td>There is one page information in pharmaceutical development report (CTD Module 3 3.2.P.2.5) regarding selection of preservative concentration.</td>
</tr>
</tbody>
</table>
Table 2  STABILITY DATA REQUIRED FOR FILEABILITY

<table>
<thead>
<tr>
<th>STABILITY DATA REQUESTED</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Does the NDA include 12 or more months of stability data?</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>2  Does the stability data cover the expiry date?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>3  Does the stability data include only the largest &amp; smallest container sizes?</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>4  Does the stability data include all packages sizes?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>5  Are there tabular data for each size and batch?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>6  Are there graphical data for each size and batch?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>7  Is a statistical consult required?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>8  Is a stability protocol included?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>9  Are the stability-indicating assays described?</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>10 Is there the three-point stability commitment?</td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>

Table 3  DMF INFORMATION

<table>
<thead>
<tr>
<th>DMF #</th>
<th>DMF HOLDER</th>
<th>TYPE</th>
<th>LOA DATE</th>
<th>DATE OF LAST REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) (4)</td>
<td>(b) (4)</td>
<td>Type II</td>
<td>8/13/04</td>
<td>9/14/03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Type II</td>
<td>8/11/04</td>
<td>6/6/04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Type III</td>
<td>1/20/04</td>
<td>5/6/04</td>
</tr>
</tbody>
</table>

COMPLETION DATE: Oct. 13, 2004

Shulin Ding, Ph.D.
Review Chemist, HFD 510

Mamta Gautam-Basak, Ph.D.
Chemistry Team Leader, HFD 510

Attachment

Cc: Original NDA
HFD-540/Division File
HFD-510/Chm/SDing
HFD-510/ChmTL/MGautam-Basak
HFD-540/ProjMgr/MCwens
HFD-830/DivDir/DLin
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------

Shulin Ding
10/13/04 02:48:07 PM
CHEMIST

Mamta Gautam-Basak
10/13/04 02:51:30 PM
CHEMIST
Concur